News RevMed hails first-line data with pancreatic cancer drug Revolution Medicine's fast-growing pan-RAS inhibitor Rasonque has generated exciting results as a first-line treatment for pancreatic cancer.
News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
News Novo says Wegovy shot works in childhood obesity Novo has published the results of a trial of its Wegovy injection in children aged six to 12 with obesity, showing the drug reduced their BMI.
News Helus shares slide on psychedelic readout in depression Helus has revealed data from a phase 3 trial of HLP003 that showed evidence of efficacy in depression, although its shares fell on safety concerns.
News UK's Levicept builds case for osteoarthritis therapy at ACR New data on Levicept's LEVI-04 in patients with osteoarthritis support its potential to become the first new systemic treatment in over two decades.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.